LONDON BROKER RATINGS: Berenberg cuts Rio Tinto and BofA lowers Anto
7th Jul 2022 10:30
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - Stock prices in London are seen opening higher on Tuesday, continuing a somewhat confident start to the third quarter for equities, despite inflationary and recessionary fears showing little sign of fading. Read More
(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates. Read More
(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine. Read More
(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day. Read More
(Alliance News) - AstraZeneca PLC on Thursday said its antibody Imfinzi, when used with chemotherapy, significantly improved responses in a form of cell lung cancer. Read More
Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going." Read More
(Alliance News) - Stock prices in London opened higher on Monday amid hopes of less aggressive monetary policy tightening by central banks, while Biffa shares fell after a delay to the publication of its annual results. Read More
(Alliance News) - AstraZeneca PLC said on Monday that its breast cancer treatments, Lynparza and Enhertu, have been recommended for approval in the EU. Read More
(Alliance News) - Stock prices in London are seen opening higher on Monday following a strong close in the US on Friday and a rally across Asian markets, amid gatherings of world leaders and central bankers at separate meetings in Europe this week. Read More
(Alliance News) - AstraZeneca PLC on Thursday reported strong results from phase III clinical trials for ALXN1840. Read More
(Alliance News) - Merck & Co Inc on Tuesday said its Lynparza drug, developed alongside AstraZeneca PLC, improved survival rates for some sufferers of prostate cancer. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said eplontersen, its candidate for a form of hereditary polyneuropathy, demonstrated significant positive results in a phase 3 trial interim analysis. Read More
(Alliance News) - Tuesday's dead cat bounce didn't live past the morning in Europe, with the FTSE 100 back in the red at midday as investors fret over an upcoming US interest rate decision. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday: Read More
(Alliance News) - Average pay in the UK is failing to keep up with rampant inflation, though the country's jobless rate remains at nearly a 50-year low, posing a conundrum for the Bank of England when it meets this week. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in patients with breast cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said Calquence, when used in combination with obinutuzumab, showed a longer-term survival rate in people with a form of leukaemia. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its Evusheld antibody reduces the risk of serious Covid-19 symptoms or death from the virus in vulnerable sufferers. Read More
(Alliance News) - Equities in London had a buoyant start to the week after a four-day break, with oil majors and miners leading the gainers amid optimism over easing Covid rules in China. Read More